News | June 03, 2022
LEO Pharma strengthens its commercial organization
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
India has the second-largest number of adults with diabetes globally, after China
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Food-tech disruptor prepares to vastly scale dairy-identical, non-animal milk protein production in a pioneering sustainable industrial park in Denmark
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
Subscribe To Our Newsletter & Stay Updated
